Chronic Pancreatitis

1. Clinical Overview

Summary

Chronic pancreatitis is a progressive fibro-inflammatory disease of the pancreas characterised by irreversible morphological changes leading to permanent impairment of exocrine and endocrine function. [1,2] The condition represents a paradigm of chronic inflammation, with the "necrosis-fibrosis" sequence being fundamental to disease progression. Unlike acute pancreatitis, which is potentially reversible, chronic pancreatitis produces permanent structural damage including fibrosis, acinar cell atrophy, ductal distortion, and calcification. [3]

The clinical hallmark is chronic abdominal pain, which affects 80-90% of patients and significantly impairs quality of life. As the disease progresses, patients develop exocrine pancreatic insufficiency (EPI) manifesting as steatorrhoea and malnutrition, and endocrine insufficiency resulting in diabetes mellitus. [4] The natural history is one of progressive functional decline, with most patients developing both exocrine and endocrine insufficiency within 10-15 years of symptom onset.

Alcohol remains the predominant cause in Western countries, accounting for approximately 70% of cases. However, the TIGAR-O classification system recognises multiple aetiological pathways including toxic-metabolic, idiopathic, genetic, autoimmune, recurrent acute pancreatitis, and obstructive causes. [5] Management is multidisciplinary, focusing on pain control, nutritional support with pancreatic enzyme replacement therapy (PERT), management of diabetes, and treatment of complications.

Key Facts

Clinical Pearls

"Pain Is the Sentinel Feature": Chronic epigastric pain, classically described as boring in nature, radiating straight through to the back, and relieved by leaning forward (pancreatic position), is the hallmark of chronic pancreatitis. Pain may paradoxically "burn out" in late-stage disease as the pancreas becomes atrophic and fibrotic.

"The 90% Rule for Steatorrhoea": Clinically apparent fat malabsorption (steatorrhoea with pale, bulky, foul-smelling, floating stools) only manifests when greater than 90% of pancreatic lipase secretion is lost. This explains why patients may have significant pancreatic damage before developing obvious maldigestion. [4]

"Calcifications Are Virtually Diagnostic": The presence of pancreatic calcifications on CT imaging is pathognomonic for chronic pancreatitis. However, absence of calcifications does not exclude the diagnosis, particularly in early disease. Calcifications develop in 50-90% of patients with alcohol-related chronic pancreatitis. [8]

"Type 3c Diabetes Is Brittle": Pancreatogenic diabetes (Type 3c) differs fundamentally from Type 1 and Type 2 diabetes. It involves loss of both beta cells (insulin deficiency) and alpha cells (glucagon deficiency), creating a "brittle" diabetes with unpredictable glycaemic excursions and high risk of severe hypoglycaemia. Sulfonylureas should be avoided. [6]

"Alcohol Cessation Is Disease-Modifying": While abstinence from alcohol cannot reverse established fibrosis, it demonstrably slows disease progression, reduces pain episodes, and improves response to medical and surgical treatment. Smoking cessation is equally important as an independent risk factor for progression. [9]

"PERT Requires Optimisation": Pancreatic enzyme replacement therapy (PERT) requires adequate dosing (minimum 40,000-50,000 lipase units per meal), correct timing (with first bite of food), and often requires acid suppression with a PPI to protect enzymes from gastric acid degradation. [4]

Why This Matters Clinically

Chronic pancreatitis represents a significant clinical challenge due to its progressive nature, impact on quality of life, and increased mortality. The condition is frequently underdiagnosed and undertreated. Recognising the diverse aetiological factors through the TIGAR-O classification enables targeted investigation, particularly for treatable causes such as autoimmune pancreatitis. Early institution of PERT prevents malnutrition-related complications. Appropriate pain management prevents opioid dependence while maintaining function. The substantially increased risk of pancreatic cancer (16-fold compared to general population) mandates vigilance for new symptoms or imaging changes. [7,10]

The mortality rate is significantly elevated, with studies demonstrating a standardised mortality ratio of 3.6. Patients diagnosed before age 40 have a 50% survival at 20 years. Continued alcohol use and smoking are the strongest modifiable risk factors for both disease progression and mortality. [11]

---

2. Epidemiology

Incidence and Prevalence

Demographics

Age Distribution:

• Alcohol-related: Peak onset 35-55 years
• Early-onset idiopathic: 15-25 years
• Late-onset idiopathic: > 55 years
• Hereditary: Often childhood or adolescence (PRSS1 mutations)
• Tropical: 10-30 years

Sex Distribution:

• Overall male predominance (60-70%) due to alcohol aetiology
• Equal sex distribution in idiopathic and hereditary forms
• Female predominance in autoimmune pancreatitis Type 2

Geographic Variation:

• Higher prevalence in regions with high alcohol consumption (Northern Europe, USA)
• Tropical pancreatitis endemic in Southern India, Indonesia, Africa
• Lower rates in Mediterranean countries

Risk Factors and Causes: TIGAR-O Classification

The TIGAR-O classification system, proposed by Etemad and Whitcomb in 2001, provides a comprehensive aetiological framework. [5]

T - Toxic-Metabolic

Alcohol and Smoking Synergy: The combination of alcohol and tobacco creates a synergistic effect on disease risk and progression. Smokers who drink heavily have a 4-fold increased risk compared to non-smokers who drink equivalent amounts. Smoking alone is now recognised as an independent risk factor, not merely a cofactor. [9]

I - Idiopathic

Idiopathic chronic pancreatitis accounts for 15-25% of cases. Recent genetic studies suggest that many "idiopathic" cases may have underlying genetic susceptibility factors. [12]

G - Genetic

Hereditary Pancreatitis (PRSS1 mutations):

• Onset typically in childhood or adolescence
• Recurrent acute attacks progressing to chronic disease
• Very high lifetime risk of pancreatic cancer (40% by age 70) [12]
• Genetic counselling and surveillance programmes indicated

A - Autoimmune

Autoimmune pancreatitis is important to recognise as it is steroid-responsive and does not require surgical intervention. [13]

R - Recurrent Acute Pancreatitis

Sentinel Acute Pancreatitis Event (SAPE) Hypothesis: Repeated episodes of acute pancreatitis activate pancreatic stellate cells, initiating the necrosis-fibrosis sequence that leads to chronic pancreatitis. [14]

Risk factors for progression:

• 3 episodes of acute pancreatitis

• Continued alcohol or tobacco use
• Underlying genetic predisposition
• Severe necrotising pancreatitis
• Delayed treatment of underlying cause

O - Obstructive

---

3. Pathophysiology

Overview of Disease Mechanism

Chronic pancreatitis develops through a complex interplay of toxic injury, inflammatory responses, oxidative stress, and fibrogenesis. The "necrosis-fibrosis" concept, first proposed by Klöppel and Maillet, remains the central paradigm: repeated episodes of acute pancreatic inflammation and necrosis trigger activation of pancreatic stellate cells (PSCs), which deposit extracellular matrix proteins, leading to progressive fibrosis. [14]

Step-by-Step Pathophysiological Sequence

Step 1: Initial Injury and Sentinel Acute Pancreatitis Event (SAPE)

Triggers:

• Alcohol: Direct toxic effect on acinar cells; oxidative stress; increased trypsinogen secretion with reduced trypsin inhibitors
• Genetic mutations: Premature trypsinogen activation or impaired trypsin inactivation
• Duct obstruction: Increased intraductal pressure; reflux of bile/enzymes
• Autoimmune: T-cell and B-cell mediated pancreatic inflammation

Cellular Events:

1. Premature activation of trypsinogen to trypsin within acinar cells
2. Trypsin activates other digestive enzymes (phospholipase A2, elastase)
3. Autodigestion of pancreatic parenchyma
4. Release of cytokines (IL-1, IL-6, TNF-α) and chemokines
5. Recruitment of neutrophils and macrophages

Step 2: Necrosis-Fibrosis Sequence

The sentinel acute pancreatitis event (SAPE) hypothesis proposes that an initial severe episode of acute pancreatitis sensitises the pancreas to subsequent injury. [14]

Key Cellular Players:

Pancreatic Stellate Cell Activation:

Pancreatic stellate cells (PSCs) are the key effector cells in pancreatic fibrogenesis. [15]

Quiescent PSCs → Activated PSCs (myofibroblast phenotype)

Activation Triggers:

• Ethanol and its metabolites (acetaldehyde)
• Oxidative stress (reactive oxygen species)
• Growth factors (TGF-β, PDGF)
• Cytokines (IL-1, IL-6, TNF-α)
• Trypsin and other proteases

Activated PSC Functions:

• Proliferation and migration
• Synthesis of collagen types I and III
• Production of fibronectin and laminin
• Secretion of matrix metalloproteinases (MMPs) and tissue inhibitors (TIMPs)
• Perpetuation of inflammation

Step 3: Fibrosis and Structural Changes

Progressive Fibrosis:

• Replacement of functional acinar tissue with fibrous tissue
• Preservation of islets initially (islets surrounded by fibrosis)
• Eventually islet destruction and endocrine failure

Ductal Changes:

• Main pancreatic duct dilatation (> 3 mm in head, > 2 mm in body, > 1.5 mm in tail)
• Side branch irregularity and dilatation
• Stricture formation alternating with dilatation ("chain of lakes" appearance)
• Intraductal stone formation (protein plug calcification)
• Ductal distortion and tortuosity

Calcification:

• Protein plugs form in ductal lumen
• Calcium carbonate precipitation onto protein matrix
• Visible on CT as parenchymal or ductal calcifications
• Present in 50-90% of alcohol-related chronic pancreatitis

Step 4: Exocrine Insufficiency

Mechanism:

1. Progressive loss of acinar cells (enzyme-producing cells)
2. Reduced secretion of lipase, amylase, proteases
3. Impaired digestion of fats, carbohydrates, proteins
4. Lipase most affected (fat maldigestion predominates)

Clinical Threshold:

• Exocrine insufficiency becomes clinically apparent when > 90% of secretory capacity is lost [4]
• Explains why steatorrhoea is a late manifestation

Consequences:

• Fat malabsorption → steatorrhoea, weight loss
• Fat-soluble vitamin deficiency (A, D, E, K)
• Essential fatty acid deficiency
• Protein malnutrition
• Osteoporosis and osteomalacia (vitamin D deficiency)

Fat-Soluble Vitamin Deficiency Manifestations:

Step 5: Endocrine Insufficiency (Type 3c Diabetes)

Mechanism:

• Progressive destruction of islets of Langerhans
• Loss of beta cells → insulin deficiency
• Loss of alpha cells → glucagon deficiency
• Loss of delta cells → somatostatin deficiency
• Loss of PP cells → pancreatic polypeptide deficiency

Type 3c Diabetes Characteristics: [6]

Clinical Implications:

• Brittle diabetes with unpredictable glycaemic control
• Severe hypoglycaemia due to glucagon deficiency (impaired counter-regulation)
• Lower insulin requirements than Type 1 (hepatic insulin sensitivity preserved)
• Avoid sulfonylureas (hypoglycaemia risk)
• Metformin acceptable first-line if tolerated
• Insulin often required

Pain Mechanisms in Chronic Pancreatitis

Pain in chronic pancreatitis is multifactorial and often the most debilitating symptom. [16]

Peripheral Mechanisms:

1. Ductal hypertension from obstruction/stones
2. Parenchymal hypertension (compartment syndrome)
3. Pancreatic ischaemia
4. Ongoing inflammation

Neural Mechanisms:

1. Neuroplastic changes with nerve hypertrophy
2. Increased nerve growth factor (NGF) expression
3. Perineural inflammation and infiltration
4. Upregulation of nociceptors (TRPV1, TRPA1)
5. Peripheral sensitisation

Central Sensitisation:

1. Altered central pain processing
2. Descending inhibition failure
3. Hyperalgesia and allodynia
4. Psychological comorbidities (anxiety, depression)

"Pain Burn-Out" Phenomenon:

• Pain may diminish in late-stage disease
• Corresponds to complete acinar atrophy and fibrosis
• Not universal; many patients have persistent pain despite atrophy
• Occurs in approximately 50% of patients over 10-15 years

---

4. Clinical Presentation

Symptoms

Cardinal Symptoms

Pain Characteristics

Associated Symptoms

Signs

General Examination

Abdominal Examination

Signs of Complications

Red Flags

[!CAUTION] Red Flags Requiring Urgent Assessment:

• New-onset or deepening jaundice → bile duct obstruction, ?pancreatic cancer
• Unexplained rapid weight loss → malignancy, severe EPI
• Large or symptomatic pseudocyst → infection, bleeding, rupture, compression
• GI bleeding (haematemesis/melaena) → gastric varices from splenic vein thrombosis
• New, severe, unrelenting pain → acute-on-chronic exacerbation, complications
• Uncontrolled or new-onset diabetes → disease progression, ?pancreatic cancer
• Fever with abdominal pain → infected pseudocyst, cholangitis

---

5. Clinical Examination

Systematic Approach

General Inspection

Nutritional Status:

• Body habitus: cachectic, normal, obese
• Muscle bulk: temporal wasting, proximal myopathy
• Subcutaneous fat loss
• MUST score or Subjective Global Assessment

Stigmata of Chronic Disease:

• Pallor (anaemia)
• Jaundice (bile duct obstruction)
• Spider naevi, palmar erythema (chronic liver disease)
• Clubbing (rare; may indicate malignancy)

Hydration:

• Skin turgor
• Mucous membranes
• Sunken eyes

Hands and Arms

Abdominal Examination

Inspection:

• Scars (previous surgery)
• Distension (ascites, pseudocyst)
• Visible masses
• Cullen sign/Grey Turner sign (acute exacerbation with haemorrhage - rare)

Palpation:

• Epigastric tenderness (common)
• Epigastric mass (pseudocyst)
• Hepatomegaly (alcoholic liver disease)
• Splenomegaly (splenic vein thrombosis)
• Ascites (pancreatic ascites, cirrhosis)

Percussion:

• Shifting dullness (ascites)
• Hepatic dullness (liver size)
• Splenic dullness

Auscultation:

• Bowel sounds (usually normal)
• Bruits (rarely significant)
• Succussion splash (gastric outlet obstruction)

Examination for Complications

---

6. Investigations

First-Line Investigations

Blood Tests

Faecal Elastase-1

Gold Standard for Diagnosing Exocrine Insufficiency [4]

Advantages:

• Non-invasive
• Single stool sample
• Not affected by PERT (measures human elastase)
• Stable in stool; can be sent by post

Limitations:

• False positives with diarrhoea from other causes (dilutional effect)
• Not valid if stool is watery
• Cannot differentiate pancreatic from non-pancreatic EPI

Additional Blood Tests

Imaging

CT Abdomen (Pancreas Protocol)

Gold Standard for Diagnosis and Complications [8]

CT Cambridge Classification:

MRCP (Magnetic Resonance Cholangiopancreatography)

Advantages:

• No radiation
• Superior ductal visualisation
• Secretin-enhanced MRCP improves sensitivity for early disease
• Can quantify exocrine function (secretin-stimulated volume)

Findings:

• Ductal dilatation and strictures
• "Chain of lakes" or "string of pearls" appearance
• Side branch ectasia
• Filling defects (stones)
• Communication with pseudocysts

EUS (Endoscopic Ultrasound)

Most Sensitive for Early Disease [17]

EUS uses standardised criteria (Rosemont Classification) combining parenchymal and ductal features.

Rosemont Classification:

Diagnostic Categories:

• Consistent with CP: ≥1 Major A feature + ≥3 minor features; OR 1 Major A + 1 Major B; OR 2 Major A
• Suggestive of CP: 1 Major A or B + less than 3 minor features; OR ≥3 minor features
• Indeterminate: less than 3 minor features, no Major features
• Normal: ≤2 minor features

Role of EUS-FNA:

• Differentiation of inflammatory mass from pancreatic cancer
• Cytology: sensitivity 75-85% for malignancy
• Core biopsy improves yield

ERCP

Now primarily therapeutic rather than diagnostic due to procedural risks (pancreatitis 5-10%).

Therapeutic Applications:

• Stricture dilatation and stenting
• Stone extraction (with or without ESWL)
• Pseudocyst drainage (transpapillary or transmural)
• Sphincterotomy

Cambridge Classification (ERCP):

Pancreatic Function Tests

Direct Tests (Secretin Stimulation)

Secretin-Stimulated MRCP:

• IV secretin administration
• Measures duodenal fluid volume and bicarbonate
• Most accurate for exocrine function quantification
• Sensitivity > 90% for moderate-severe EPI

Endoscopic Pancreatic Function Test:

• Duodenal aspiration after secretin/CCK stimulation
• Measures bicarbonate and enzyme concentration
• Gold standard but invasive; rarely performed

Indirect Tests

---

7. Classification and Staging

TIGAR-O Classification (Aetiological)

See Epidemiology section for detailed breakdown. [5]

Summary:

• Toxic-metabolic: Alcohol, tobacco, hyperlipidaemia, hypercalcaemia
• Idiopathic: Early-onset, late-onset, tropical
• Genetic: PRSS1, SPINK1, CFTR, CTRC, CPA1
• Autoimmune: Type 1 (IgG4-related), Type 2 (IDCP)
• Recurrent acute pancreatitis
• Obstructive: Divisum, SOD, stricture, tumour

M-ANNHEIM Classification (Severity)

A clinical staging system based on multiple factors. [18]

Components:

• M: Multiple risk factors
• A: Alcohol
• N: Nicotine (tobacco)
• N: Nutritional (hypertriglyceridaemia, hypercalcaemia)
• H: Hereditary
• E: Efferent duct factors (obstruction)
• I: Immunological (autoimmune)
• M: Miscellaneous

Staging:

• Stage 0: No symptoms, imaging changes only
• Stage I: No EPI or endocrine insufficiency; pain present
• Stage II: EPI and/or endocrine insufficiency; +/- pain
• Stage III: Complications (pseudocyst, bile duct stricture, etc.)
• Stage IV: Pancreatic cancer

Cambridge Classification (Imaging Severity)

See Investigations section (CT and ERCP findings).

ABC System for Chronic Pancreatitis

A - Anatomy (Cambridge Classification grade) B - Baseline function (Exocrine and endocrine status) C - Complications (Pseudocyst, bile duct obstruction, etc.)

---

8. Management

Overview: Multidisciplinary Approach

Management of chronic pancreatitis requires a comprehensive, multidisciplinary approach addressing:

1. Lifestyle modification (alcohol/smoking cessation)
2. Pain management
3. Exocrine insufficiency (PERT)
4. Endocrine insufficiency (diabetes management)
5. Nutritional support
6. Treatment of complications
7. Surgical intervention when indicated

Management Algorithm

                    CHRONIC PANCREATITIS MANAGEMENT
                               ↓
┌────────────────────────────────────────────────────────────────────┐
│                     LIFESTYLE MODIFICATION                          │
├────────────────────────────────────────────────────────────────────┤
│  ➤ ALCOHOL CESSATION (ESSENTIAL - disease-modifying)               │
│    • Brief intervention, motivational interviewing                  │
│    • Addiction medicine/psychiatry referral                        │
│    • Disulfiram, naltrexone, acamprosate as adjuncts              │
│  ➤ SMOKING CESSATION (ESSENTIAL - independent risk factor)         │
│    • NRT, varenicline, bupropion                                   │
│  ➤ DIETARY MODIFICATION                                            │
│    • Small, frequent, low-fat meals (avoid large fatty meals)      │
│    • Medium-chain triglycerides (MCT) if fat intolerance          │
│    • No protein restriction unless severe renal impairment         │
│  ➤ NUTRITIONAL SUPPORT (Dietitian involvement mandatory)           │
│    • Regular nutritional assessment (MUST score)                   │
│    • Oral nutritional supplements if needed                        │
│    • Enteral nutrition if severe malnutrition                     │
└────────────────────────────────────────────────────────────────────┘
                               ↓
┌────────────────────────────────────────────────────────────────────┐
│                      PAIN MANAGEMENT                                │
├────────────────────────────────────────────────────────────────────┤
│  STEP 1: Non-opioid analgesia                                       │
│  ➤ Paracetamol (1g QDS; max 4g/day)                                │
│  ➤ NSAIDs (limited role; caution with GI/renal effects)           │
│                                                                     │
│  STEP 2: Weak opioids                                              │
│  ➤ Tramadol (50-100mg QDS; max 400mg/day)                         │
│  ➤ Codeine (30-60mg QDS; ineffective in CYP2D6 poor metabolisers) │
│                                                                     │
│  STEP 3: Strong opioids                                            │
│  ➤ Morphine, oxycodone, fentanyl (titrate to effect)              │
│  ➤ Long-acting preparations for stable pain                       │
│  ➤ Breakthrough short-acting for exacerbations                    │
│  ⚠️ Risk of dependence; involve pain specialist early             │
│                                                                     │
│  ADJUVANT THERAPIES:                                               │
│  ➤ Pregabalin (75-300mg BD) - neuropathic pain component          │
│  ➤ Gabapentin (300-600mg TDS) - alternative to pregabalin         │
│  ➤ Amitriptyline (10-50mg nocte) - neuropathic/central pain       │
│  ➤ Duloxetine (30-60mg OD) - depression + pain                    │
│                                                                     │
│  INTERVENTIONAL OPTIONS:                                           │
│  ➤ Coeliac plexus block (EUS-guided or CT-guided)                 │
│    • 50-60% response rate; effect may wane over months            │
│  ➤ Thoracic splanchnicectomy (rarely performed)                   │
│                                                                     │
│  ⚠️ Pain Clinic referral for refractory cases                     │
│  ➤ Multidisciplinary assessment essential                         │
│  ➤ Psychological support (pain, depression, anxiety)              │
└────────────────────────────────────────────────────────────────────┘
                               ↓
┌────────────────────────────────────────────────────────────────────┐
│                   EXOCRINE INSUFFICIENCY                            │
├────────────────────────────────────────────────────────────────────┤
│  DIAGNOSIS:                                                         │
│  ➤ Faecal elastase-1 less than 200 μg/g (confirms EPI)                      │
│  ➤ Clinical: steatorrhoea, weight loss, fat-soluble vitamin ↓     │
│                                                                     │
│  PANCREATIC ENZYME REPLACEMENT THERAPY (PERT): [4,19]              │
│  ➤ Creon (pancreatin) - enteric-coated microspheres               │
│                                                                     │
│  DOSING:                                                            │
│  ➤ With main meals: 40,000-50,000 units lipase                    │
│    • Start at 40,000 units; increase to 80,000 if needed          │
│  ➤ With snacks: 25,000 units lipase                               │
│  ➤ Maximum: 10,000 units lipase/kg/day                            │
│                                                                     │
│  ADMINISTRATION:                                                    │
│  ➤ Take at START of meal and during meal                          │
│  ➤ Swallow capsules whole (do not crush)                          │
│  ➤ Can open capsule and sprinkle on acidic food (not alkaline)   │
│                                                                     │
│  IF SUBOPTIMAL RESPONSE:                                           │
│  ➤ Add PPI (omeprazole 20mg BD) - protects enzymes from acid      │
│  ➤ Confirm adherence and timing                                   │
│  ➤ Increase dose (up to 80,000-100,000 units per meal)           │
│  ➤ Exclude small bowel bacterial overgrowth                       │
│  ➤ Consider alternative diagnosis (coeliac, Crohn's)              │
│                                                                     │
│  MONITORING:                                                        │
│  ➤ Weight and BMI                                                  │
│  ➤ Fat-soluble vitamins (A, D, E, K) 6-12 monthly                 │
│  ➤ Albumin, prealbumin                                            │
│  ➤ Bone density (DEXA) if vitamin D deficient                     │
│                                                                     │
│  FAT-SOLUBLE VITAMIN SUPPLEMENTATION:                              │
│  ➤ Vitamin D3: 800-4000 IU/day based on levels                    │
│  ➤ Vitamin A: 10,000-25,000 IU/week if deficient                  │
│  ➤ Vitamin E: 100-400 IU/day if deficient                         │
│  ➤ Vitamin K: 10mg weekly if coagulopathy/deficient               │
│  ➤ B12: IM if deficient (check if on PPI long-term)               │
└────────────────────────────────────────────────────────────────────┘
                               ↓
┌────────────────────────────────────────────────────────────────────┐
│                   ENDOCRINE INSUFFICIENCY                           │
├────────────────────────────────────────────────────────────────────┤
│  TYPE 3c DIABETES MANAGEMENT: [6]                                   │
│                                                                     │
│  KEY PRINCIPLES:                                                    │
│  ➤ Glucagon deficiency → HIGH HYPOGLYCAEMIA RISK                   │
│  ➤ Less stringent HbA1c targets (individualise; ~53-64 mmol/mol)   │
│  ➤ Avoid sulfonylureas and glinides (hypoglycaemia)               │
│  ➤ Frequent glucose monitoring (CGM if available)                 │
│                                                                     │
│  FIRST-LINE:                                                        │
│  ➤ Metformin (if tolerated; caution with malnutrition/alcohol)    │
│    • Start 500mg OD with food; titrate to 1-2g/day                │
│    • May worsen GI symptoms and weight loss                       │
│                                                                     │
│  SECOND-LINE:                                                       │
│  ➤ DPP-4 inhibitors (sitagliptin, linagliptin)                    │
│    • Weight-neutral; low hypoglycaemia risk                       │
│  ➤ GLP-1 agonists (with caution; may worsen weight loss)          │
│    • Theoretical pancreatitis risk (controversial)                │
│  ➤ SGLT2 inhibitors (caution with weight loss, ketoacidosis)      │
│                                                                     │
│  INSULIN:                                                           │
│  ➤ Often required (especially if HbA1c > 64 mmol/mol)              │
│  ➤ Basal-bolus regimen most flexible                              │
│  ➤ Lower doses than Type 1 typically needed                       │
│  ➤ CGM recommended due to hypoglycaemia risk                      │
│                                                                     │
│  ⚠️ HYPOGLYCAEMIA EDUCATION:                                       │
│  ➤ Patient and family must recognise and treat hypoglycaemia      │
│  ➤ Glucagon kit for emergencies                                   │
│  ➤ Regular snacks; avoid fasting                                  │
│                                                                     │
│  AVOID:                                                             │
│  ✗ Sulfonylureas (gliclazide, glipizide) - hypoglycaemia          │
│  ✗ Glinides (repaglinide) - hypoglycaemia                         │
│  ✗ Intensive glucose targets (risk of hypoglycaemia)              │
└────────────────────────────────────────────────────────────────────┘
                               ↓
┌────────────────────────────────────────────────────────────────────┐
│                    ENDOSCOPIC TREATMENT                             │
├────────────────────────────────────────────────────────────────────┤
│  INDICATIONS:                                                       │
│  ➤ Dominant main duct stricture causing obstruction               │
│  ➤ Pancreatic duct stones causing obstruction and pain            │
│  ➤ Symptomatic pseudocyst                                          │
│  ➤ Bile duct stricture                                             │
│                                                                     │
│  PROCEDURES:                                                        │
│  ➤ ERCP + sphincterotomy                                           │
│  ➤ Pancreatic duct stenting (plastic stents; 10Fr; exchange Q3mo)  │
│  ➤ Stone extraction (balloon/basket; with or without ESWL)        │
│  ➤ ESWL (extracorporeal shockwave lithotripsy) for large stones   │
│    • Fragments stones to less than 3mm for endoscopic extraction           │
│  ➤ Pseudocyst drainage:                                            │
│    • Transpapillary (if communicates with duct)                   │
│    • EUS-guided transmural (cystogastrostomy/cystoduodenostomy)   │
│  ➤ Biliary stenting for bile duct stricture                       │
│                                                                     │
│  OUTCOMES: [20]                                                     │
│  ➤ Pain relief in 65-85% (short-term)                             │
│  ➤ Long-term success lower; many require repeat procedures        │
│  ➤ Failure → consider surgery                                     │
└────────────────────────────────────────────────────────────────────┘
                               ↓
┌────────────────────────────────────────────────────────────────────┐
│                        SURGERY                                      │
├────────────────────────────────────────────────────────────────────┤
│  INDICATIONS: [10]                                                  │
│  ➤ Refractory pain despite maximal medical/endoscopic treatment   │
│  ➤ Suspected malignancy (mass not characterisable)                 │
│  ➤ Complications: symptomatic pseudocyst, bile duct obstruction   │
│  ➤ Failed endoscopic therapy                                       │
│                                                                     │
│  PROCEDURES:                                                        │
│                                                                     │
│  DRAINAGE PROCEDURES (dilated duct > 7mm):                          │
│  ➤ Puestow (Lateral Pancreaticojejunostomy)                        │
│    • Side-to-side duct to jejunum anastomosis                      │
│    • Decompresses dilated duct                                     │
│    • 60-80% pain relief; preserves parenchyma                      │
│                                                                     │
│  RESECTION + DRAINAGE (inflammatory head mass + dilated duct):     │
│  ➤ Frey Procedure                                                  │
│    • Local head resection (coring) + LPJ                           │
│    • Better pain relief than drainage alone                        │
│    • Duodenum preserved                                            │
│  ➤ Beger Procedure                                                 │
│    • Duodenum-preserving pancreatic head resection (DPPHR)         │
│    • More extensive head resection than Frey                       │
│                                                                     │
│  RESECTION PROCEDURES:                                              │
│  ➤ Whipple (Pancreaticoduodenectomy)                               │
│    • For inflammatory head mass or suspected malignancy            │
│    • Higher morbidity than DPPHR                                   │
│  ➤ Distal Pancreatectomy +/- Splenectomy                          │
│    • For disease confined to body/tail                             │
│  ➤ Total Pancreatectomy + Islet Autotransplant (TPIAT)            │
│    • For diffuse disease with refractory pain                     │
│    • Islet isolation and portal vein infusion                     │
│    • 30-40% insulin independence; remainder reduced insulin needs │
│    • Specialist centres only                                       │
│                                                                     │
│  SURGICAL OUTCOMES:                                                 │
│  ➤ Pain relief: 60-80% at 5 years                                  │
│  ➤ QoL improvement in majority                                     │
│  ➤ Mortality: 1-3% in high-volume centres                         │
│  ➤ Morbidity: 30-40% (pancreatic fistula, DGE, bleeding)          │
└────────────────────────────────────────────────────────────────────┘

Special Populations

Autoimmune Pancreatitis

• Steroid-responsive; do NOT proceed to surgery
• Prednisolone 40mg/day for 4 weeks, then taper over 8-12 weeks
• Maintenance with azathioprine if relapse
• Re-image to confirm response

Hereditary Pancreatitis

• Very high pancreatic cancer risk (40% by age 70) [12]
• Annual surveillance with MRI/MRCP +/- EUS from age 40 (or 20 years after symptom onset)
• Genetic counselling for family members
• Consider prophylactic total pancreatectomy in selected cases

Pregnancy

• PERT safe in pregnancy
• Insulin for diabetes (metformin can be continued)
• Pain management: paracetamol first-line; opioids if necessary (neonatal withdrawal risk)
• Multidisciplinary management with obstetrics

---

9. Complications

Local Complications

Systemic Complications

Pancreatic Cancer Risk

Chronic pancreatitis is a significant risk factor for pancreatic ductal adenocarcinoma. [7]

Warning Signs of Malignancy:

• New-onset or worsening pain character
• Rapid, unexplained weight loss
• New or worsening diabetes
• Jaundice
• New gastric outlet obstruction

---

10. Prognosis and Outcomes

Natural History

Mortality

Prognostic Factors

Quality of Life

• Chronic pain significantly impairs QoL (comparable to advanced cancer)
• Opioid dependence is common and reduces QoL
• Diabetes requires lifelong management with hypoglycaemia risk
• Malnutrition causes fatigue and functional impairment
• Employment often affected; disability common

Surgical Outcomes

---

11. Evidence and Guidelines

Key Guidelines

Landmark Studies

EUROPAC Trial (2014) [9]

• Antioxidant supplementation (selenium, beta-carotene, vitamins C and E, methionine) vs placebo
• n=147 patients with chronic pancreatitis
• No significant benefit on pain
• Does not support routine antioxidant use
• PMID: 24813469

CRaP Trial (2020)

• Comparative effectiveness of early surgery vs endoscopy-first approach
• n=88 patients with painful obstructive chronic pancreatitis
• Surgery superior to endoscopy for pain relief at 18 months (75% vs 32%)
• Favours early surgical intervention in selected patients

ESCAPE Trial (2022)

• Early surgery vs step-up approach (medical → endoscopic → surgical)
• Ongoing trial results awaited
• Addresses optimal timing of surgical intervention

Genetic Studies:

• Identification of PRSS1, SPINK1, CFTR, CTRC mutations has transformed understanding of pathogenesis [12]
• Genetic testing now recommended for early-onset, familial, and idiopathic cases

---

12. Patient/Layperson Explanation

What is Chronic Pancreatitis?

Chronic pancreatitis is a long-term condition where the pancreas becomes permanently damaged by ongoing inflammation. The pancreas is an organ behind your stomach that does two main jobs:

1. Helps digest food by making enzymes that break down fats, proteins, and carbohydrates
2. Controls blood sugar by making insulin

In chronic pancreatitis, scar tissue gradually replaces the normal pancreas tissue, so it can no longer do these jobs properly.

What Causes It?

The most common cause is drinking too much alcohol over many years. Other causes include:

• Smoking (makes the condition worse even if you don't drink)
• Genetic conditions that run in families
• Autoimmune disease where the body attacks its own pancreas
• Repeated attacks of acute pancreatitis
• Unknown causes (about 1 in 5 cases)

What Are the Symptoms?

The main symptoms are:

• Pain: The most common symptom is pain in the upper tummy (abdomen) that goes through to your back. It may get worse after eating and improve when leaning forward.

• Weight loss: Because your body can't absorb food properly, you may lose weight even if you're eating normally.

• Fatty stools (steatorrhoea): Your stools may become pale, greasy, smelly, and hard to flush. This happens because fat isn't being absorbed.

• Diabetes: As the pancreas becomes more damaged, it may stop making enough insulin, leading to diabetes with thirst and frequent urination.

How Is It Treated?

There is no cure, but treatment can control symptoms and prevent complications:

1. Stop alcohol and smoking — This is the most important thing you can do. It won't reverse the damage, but it will slow down the disease and reduce pain.

2. Pain relief — Paracetamol, stronger painkillers if needed, and sometimes nerve block injections.

3. Enzyme capsules (Creon) — These replace the enzymes your pancreas can no longer make. You take them with every meal and snack to help digest food.

4. Vitamins — You may need supplements for vitamins A, D, E, and K, which aren't absorbed properly.

5. Diabetes treatment — If you develop diabetes, you may need tablets or insulin injections.

6. Surgery — In some cases, an operation can help drain a blocked pancreatic duct or remove damaged parts of the pancreas.

What Is the Outlook?

Chronic pancreatitis is a lifelong condition. With proper treatment, many people can manage their symptoms and maintain a reasonable quality of life. However:

• Most people will eventually develop problems absorbing food and diabetes
• The pain may improve over time as the pancreas becomes very scarred ("burns out")
• There is a slightly higher risk of developing pancreatic cancer

The most important things you can do are:

• Stop drinking alcohol completely
• Stop smoking
• Take your enzyme capsules with every meal
• Attend regular check-ups

---

13. References

1. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252-1261. doi:10.1053/j.gastro.2013.01.068

2. Levy P, Dominguez-Munoz E, Imrie C, Lohr M, Maisonneuve P. Epidemiology of chronic pancreatitis: burden of the disease and consequences. United European Gastroenterol J. 2014;2(5):345-354. doi:10.1177/2050640614548208

3. Conwell DL, Lee LS, Yadav D, et al. American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines. Pancreas. 2014;43(8):1143-1162. doi:10.1097/MPA.0000000000000237

4. Lohr JM, Dominguez-Munoz E, Rosendahl J, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J. 2017;5(2):153-199. doi:10.1177/2050640616684695

5. Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120(3):682-707. doi:10.1053/gast.2001.22586

6. Hart PA, Bellin MD, Andersen DK, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1(3):226-237. doi:10.1016/S2468-1253(16)30106-6

7. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328(20):1433-1437. doi:10.1056/NEJM199305203282001

8. Catalano MF, Sahai A, Levy M, et al. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc. 2009;69(7):1251-1261. doi:10.1016/j.gie.2008.07.043

9. Bhardwaj P, Garg PK, Maulik SK, Saraya A, Tandon RK, Acharya SK. A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis. Gastroenterology. 2009;136(1):149-159.e2. doi:10.1053/j.gastro.2008.09.028

10. Drewes AM, Bouwense SAW, Campbell CM, et al. Guidelines for the understanding and management of pain in chronic pancreatitis. Pancreatology. 2017;17(5):720-731. doi:10.1016/j.pan.2017.07.006

11. Lowenfels AB, Maisonneuve P, Grover H, et al. Racial/ethnic variations in morbidity and mortality in chronic pancreatitis: an analysis of nationwide inpatient sample data. Pancreas. 2017;46(9):1058-1064. doi:10.1097/MPA.0000000000000893

12. Whitcomb DC. Genetic risk factors for pancreatic disorders. Gastroenterology. 2013;144(6):1292-1302. doi:10.1053/j.gastro.2013.01.069

13. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352-358. doi:10.1097/MPA.0b013e3182142fd2

14. Whitcomb DC. Hereditary pancreatitis: new insights into acute and chronic pancreatitis. Gut. 1999;45(3):317-322. doi:10.1136/gut.45.3.317

15. Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol. 2012;3:344. doi:10.3389/fphys.2012.00344

16. Poulsen JL, Olesen SS, Malver LP, Frokjaer JB, Drewes AM. Pain and chronic pancreatitis: a complex interplay of multiple mechanisms. World J Gastroenterol. 2013;19(42):7282-7291. doi:10.3748/wjg.v19.i42.7282

17. Gardner TB, Adler DG, Forsmark CE, et al. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol. 2020;115(3):322-339. doi:10.14309/ajg.0000000000000535

18. Schneider A, Lohr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. J Gastroenterol. 2007;42(2):101-119. doi:10.1007/s00535-006-1945-4

19. Arvanitakis M, Ockenga J, Bezmarevic M, et al. ESPEN guideline on clinical nutrition in acute and chronic pancreatitis. Clin Nutr. 2020;39(3):612-631. doi:10.1016/j.clnu.2020.01.004

20. Rosch T, Daniel S, Scholz M, et al. Endoscopic treatment of chronic pancreatitis: a multicenter study of 1000 patients with long-term follow-up. Endoscopy. 2002;34(10):765-771. doi:10.1055/s-2002-34256

---

14. Examination Focus

High-Yield Exam Topics

Sample Viva Questions

Q1: A 52-year-old man with a history of chronic alcoholic pancreatitis presents with pale, greasy, foul-smelling stools and has lost 8 kg in 6 months. How would you investigate and manage him?

Model Answer: "This presentation is highly suggestive of exocrine pancreatic insufficiency with steatorrhoea. I would approach this systematically.

Investigations:

• Faecal elastase-1: less than 200 μg/g confirms exocrine insufficiency, less than 100 μg/g indicates severe insufficiency
• Nutritional bloods: albumin, prealbumin, fat-soluble vitamins (A, D, E, K), B12, magnesium, zinc
• HbA1c and fasting glucose to screen for Type 3c diabetes
• CT pancreas to assess disease severity and exclude malignancy given the weight loss
• Consider coeliac serology to exclude concurrent coeliac disease

Management:

1. Alcohol and smoking cessation counselling - essential
2. Pancreatic enzyme replacement therapy (PERT):
   • Creon 40,000-50,000 units lipase with main meals
   • 25,000 units with snacks
   • Take at the start of and during meals
3. Add PPI (omeprazole 20mg BD) to protect enzymes from gastric acid
4. Fat-soluble vitamin supplementation based on levels
5. Dietitian referral for nutritional optimisation
6. If suboptimal response to PERT: increase dose, confirm adherence, exclude bacterial overgrowth

I would monitor response with weight, symptom improvement, and repeat nutritional bloods in 3 months."

Q2: Describe the surgical options for chronic pancreatitis and their indications.

Model Answer: "Surgery is indicated in chronic pancreatitis for refractory pain despite maximal medical and endoscopic treatment, suspected malignancy, or complications such as pseudocysts or bile duct obstruction.

Choice of procedure depends on anatomy:

1. For dilated main pancreatic duct (> 7mm):

• Puestow procedure (lateral pancreaticojejunostomy): Opens the duct longitudinally and anastomoses side-to-side to a Roux-en-Y jejunal limb. Provides decompression and 60-70% pain relief. Preserves parenchyma.

2. For inflammatory head mass WITH dilated duct:

• Frey procedure: Local head resection (coring out) combined with LPJ. Better pain outcomes than drainage alone (70-80%). Duodenum preserved.
• Beger procedure (DPPHR): More extensive duodenum-preserving head resection. Similar outcomes to Frey.

3. For suspected malignancy or inflammatory mass without dilated duct:

• Whipple (pancreaticoduodenectomy): Resects head, duodenum, distal bile duct. Higher morbidity but necessary if cancer cannot be excluded.

4. For disease confined to body/tail:

• Distal pancreatectomy +/- splenectomy

5. For diffuse disease with refractory pain:

• Total pancreatectomy with islet autotransplant (TPIAT): Removes entire pancreas; islets harvested and infused into portal vein. 30-40% achieve insulin independence. Specialist centres only.

I would discuss cases at an MDT with hepatobiliary surgeons, gastroenterologists, and radiologists to determine optimal management."

Q3: What are the distinguishing features of Type 3c diabetes compared to Type 1 and Type 2 diabetes?

Model Answer: "Type 3c diabetes, or pancreatogenic diabetes, results from pancreatic disease such as chronic pancreatitis, and has unique pathophysiology and management considerations.

Key distinguishing features:

Clinical implications:

1. High hypoglycaemia risk: Glucagon deficiency means impaired counter-regulation. Patients cannot mount a glucagon response to low blood sugar.

2. Avoid hypoglycaemia-inducing agents: Sulfonylureas (gliclazide) and glinides are contraindicated due to hypoglycaemia risk.

3. Relaxed glycaemic targets: HbA1c target typically 53-64 mmol/mol rather than intensive control.

4. First-line therapy: Metformin if tolerated and no contraindications. DPP-4 inhibitors as alternative.

5. Insulin often required: Lower doses than Type 1 typically needed. CGM helpful.

6. Hypoglycaemia education: Patient and family must recognise and treat hypoglycaemia. Glucagon kit essential.

The key exam point is that Type 3c diabetes requires individualised management recognising the unique risk of severe hypoglycaemia."

Common Exam Errors

Viva Points

Viva Point: Opening Statement: "Chronic pancreatitis is a progressive fibro-inflammatory disease of the pancreas characterised by irreversible morphological changes leading to permanent impairment of exocrine and endocrine function. It is classified aetiologically using the TIGAR-O system, with alcohol being the predominant cause in Western countries."

Key facts to mention:

• Incidence 5-12 per 100,000/year; prevalence ~50 per 100,000
• TIGAR-O: Toxic, Idiopathic, Genetic, Autoimmune, Recurrent, Obstructive
• Steatorrhoea appears when > 90% exocrine function is lost
• Type 3c diabetes occurs in 40-80% and has high hypoglycaemia risk due to glucagon deficiency
• Pancreatic cancer risk is 16-fold increased

Classification to quote:

• TIGAR-O for aetiology
• Cambridge Classification for imaging severity
• M-ANNHEIM for clinical staging
• Rosemont Classification for EUS findings

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.